Review: Biology and relevance of C-reactive protein in cardiovascular and renal disease

C-reactive protein (CRP) is a member of the pentraxin family of proteins, which are characterised by a cyclic pentameric structure and radial symmetry. The five identical 24-kDa protomers consist of 206 amino acids, and are noncovalently linked. CRP binds to a range of substances such as phosphocholine, fibronectin, chromatin, histones, and ribonucleoprotein in a calcium-dependent manner. It is a ligand for specific receptors on phagocytic leukocytes, mediates activation reactions on monocytes and macrophages, and activates complement. Plasma CRP is the classical acute-phase protein, increasing 1,000-fold in response to infection, ischemia, trauma, burns, and inflammatory conditions. A growing number of studies suggest that CRP is an independent risk factor for atherosclerotic vascular disease. Plasma CRP concentrations in the highest quartile are associated, depending on the subject group, with 1.5- to 7-fold increases in relative risk. In the high-risk endstage renal failure population, a raised CRP is associated with up to 5.5-fold increased relative risk of CVD and 4.6-fold increased relative risk of death. This review examines the relationships between CRP, cardiovascular disease, and mortality, with special reference to renal disease.

This article has been cited by other articles:

				N. Daneshtalab, R. Z. Lewanczuk, A. S. Russell, and F. Jamali Drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis. J. Clin. Pharmacol., November 1, 2006; 46(11): 1344 - 1355. [Abstract] [Full Text] [PDF]

				D. A. Lauver, E. A. Booth, A. J. White, E. Poradosu, and B. R. Lucchesi Sulodexide Attenuates Myocardial Ischemia/Reperfusion Injury and the Deposition of C-Reactive Protein in Areas of Infarction without Affecting Hemostasis J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 794 - 800. [Abstract] [Full Text] [PDF]

				J. Westhuyzen, K. Mills, and H. Healy Predicting Clinical Outcomes in Peritoneal Dialysis Patients Using Small Solute Modeling Ann. Clin. Lab. Sci., January 1, 2005; 35(1): 46 - 53. [Abstract] [Full Text] [PDF]

				N. Daneshtalab, R. Z. Lewanczuk, A. Russell, and F. Jamali Rheumatoid Arthritis Does Not Reduce the Pharmacodynamic Response to Valsartan J. Clin. Pharmacol., March 1, 2004; 44(3): 245 - 252. [Abstract] [Full Text] [PDF]

				S. M. A. Lobo, F. R. M. Lobo, D. P. Bota, F. Lopes-Ferreira, H. M. Soliman, C. Melot, and J.-L. Vincent C-Reactive Protein Levels Correlate With Mortality and Organ Failure in Critically Ill Patients Chest, June 1, 2003; 123(6): 2043 - 2049. [Abstract] [Full Text] [PDF]

				T. D. Barrett, J. K. Hennan, R. M. Marks, and B. R. Lucchesi C-Reactive-Protein-Associated Increase in Myocardial Infarct Size After Ischemia/Reperfusion J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1007 - 1013. [Abstract] [Full Text] [PDF]

				M. Wolf, E. Kettyle, L. Sandler, J. L. Ecker, J. Roberts, and R. Thadhani Obesity and Preeclampsia: The Potential Role of Inflammation Obstet. Gynecol., November 1, 2001; 98(5): 757 - 762. [Abstract] [Full Text] [PDF]

				M. Feldman, I. Jialal, S. Devaraj, and B. Cryer Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2036 - 2041. [Abstract] [Full Text] [PDF]

				A. P. Burke, R. P. Tracy, F. Kolodgie, G. T. Malcom, A. Zieske, R. Kutys, J. Pestaner, J. Smialek, and R. Virmani Elevated C-Reactive Protein Values and Atherosclerosis in Sudden Coronary Death: Association With Different Pathologies Circulation, April 30, 2002; 105(17): 2019 - 2023. [Abstract] [Full Text] [PDF]